T2 Biosystems | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(65.4%),CR Group L.P.(65.4%), etc.
T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.
T2 Biosystems | 8-K: Amendment and Restatement Certificate of Designation of Preferences, Rights and Limitations of Convertible Preferred Stock
T2 Biosystems | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
T2 Biosystems | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
T2 Biosystems | 8-K: T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems | 10-Q: Quarterly report
T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
T2 Biosystems | S-1: General form for registration of securities under the Securities Act of 1933
T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.
T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity
T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.
T2 Biosystems | 8-K: Voting Results of Special Shareholders' Meeting
T2 Biosystems | 10-K: Annual report
T2 Biosystems | 8-K: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems | 8-K: T2 Biosystems Announces T2Lyme Commercial Launch Plan, Provides Business Update
T2 Biosystems | 8-K: T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
T2 Biosystems | 8-K: T2 Biosystems Receives Extension to Comply With Nasdaq Listing Requirement
No Data